USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination
Sha Hu1, Zhouxiang Wang1, Kun Zhu1
1Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China.
Background/Aims:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease characterized by hepatic steatosis. Ubiquitin-specific protease 29 (USP29) plays pivotal roles in hepatic ischemiareperfusion injury and hepatocellular carcinoma, but its role in MASLD remains unexplored. Therefore, the aim of this study was to reveal the effects and underlying mechanisms of USP29 in MASLD progression.
Methods:
USP29 expression was assessed in liver samples from MASLD patients and mice. The role and molecular mechanism of USP29 in MASLD were assessed in high-fat diet-fed and high-fat/high-cholesterol diet-fed mice and palmitic acid and oleic acid treated hepatocytes.
Results:
USP29 protein levels were significantly reduced in mice and humans with MASLD. Hepatic steatosis, inflammation and fibrosis were significantly exacerbated by USP29 deletion and relieved by USP29 overexpression. Mechanistically, USP29 significantly activated the expression of genes related to fatty acid β-oxidation (FAO) under metabolic stimulation, directly interacted with long-chain acyl-CoA synthase 5 (ACSL5) and repressed ACSL5 degradation by increasing ACSL5 K48-linked deubiquitination. Moreover, the effect of USP29 on hepatocyte lipid accumulation and MASLD was dependent on ACSL5.
Conclusion:
USP29 functions as a novel negative regulator of MASLD by stabilizing ACSL5 to promote FAO. The activation of the USP29-ACSL5 axis may represent a potential therapeutic strategy for MASLD.
Insights
Ubiquitin-specific protease 29 (USP29) protects against metabolic dysfunction-associated steatotic liver disease (MASLD) by stabilizing ACSL5 to enhance fatty acid oxidation. USP29 activation offers a potential therapeutic avenue for MASLD.
Area of Science:
- Hepatology
- Molecular Biology
- Biochemistry
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing health concern characterized by fat accumulation in the liver.
- The role of Ubiquitin-specific protease 29 (USP29) in MASLD pathogenesis is currently unknown.
- USP29 is implicated in other liver conditions like ischemia-reperfusion injury and hepatocellular carcinoma.
Purpose of the Study:
- To investigate the role and underlying molecular mechanisms of USP29 in the progression of MASLD.
- To determine if USP29 expression is altered in MASLD patients and animal models.
Main Methods:
- Assessed USP29 expression in human and mouse liver samples from MASLD patients and models.
- Utilized high-fat diet and high-fat/high-cholesterol diet-induced mouse models of MASLD.
- Employed palmitic acid and oleic acid treatments in cultured hepatocytes to study USP29 function.
- Investigated USP29 interaction with ACSL5 and its effect on ACSL5 degradation.
Main Results:
- USP29 protein levels were significantly decreased in MASLD patients and mice.
- USP29 deficiency exacerbated hepatic steatosis, inflammation, and fibrosis, while overexpression ameliorated these conditions.
- USP29 stabilized ACSL5 by deubiquitination, promoting fatty acid beta-oxidation (FAO).
- The protective effects of USP29 against MASLD were dependent on ACSL5.
Conclusions:
- USP29 acts as a novel negative regulator of MASLD by enhancing FAO through ACSL5 stabilization.
- The USP29-ACSL5 pathway presents a promising therapeutic target for treating MASLD.
Related Concept Videos
Anaphase Promoting Complex
Separation of Sister Chromatids
At the onset of anaphase, separase, a proteolytic enzyme, is...
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....


